BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst (Nasdaq: BCRX) announced inducement equity grants for 24 newly hired employees, comprising 251,150 stock options and 368,550 restricted stock units (RSUs) granted as of February 2, 2026, under Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
BioCryst (Nasdaq: BCRX) announced inducement equity grants for 24 newly hired employees, comprising 251,150 stock options and 368,550 restricted stock units (RSUs) granted as of February 2, 2026, under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $6.63 equal to the closing price on the grant date, vest in four equal annual installments beginning one year from grant, and each option has a 10-year term. Grants are subject to the Inducement Equity Incentive Plan and applicable award agreements.
"granted in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
stock optionsfinancial
"granted 24 newly-hired employees stock options to purchase an aggregate of 251,150"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
restricted stock unitsfinancial
"and restricted stock units (RSUs) covering an aggregate of 368,550 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
rsusfinancial
"restricted stock units (RSUs) covering an aggregate of 368,550 shares"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
exercise pricefinancial
"The options have an exercise price of $6.63 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
equity incentive planfinancial
"subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 24 newly-hired employees stock options to purchase an aggregate of 251,150 shares, and restricted stock units (RSUs) covering an aggregate of 368,550 shares, of BioCryst common stock. The options and RSUs were granted as of February 2, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $6.63 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BioCryst (BCRX) announce on February 5, 2026 about employee equity grants?
BioCryst announced inducement grants of options and RSUs to 24 new employees on February 2, 2026. According to the company, the awards total 251,150 options and 368,550 RSUs provided as material inducements to employment under Nasdaq Rule 5635(c)(4).
What are the key terms of the stock options granted by BioCryst (BCRX)?
The options have an exercise price of $6.63 and a 10-year term. According to the company, the $6.63 price equals the closing price on the grant date and each option vests in four equal annual installments starting one year after the grant.
How do the BioCryst (BCRX) RSUs and options vest for new hires?
The awards vest in four equal annual installments beginning on the one-year anniversary of the grant. According to the company, vesting is contingent on the new employee's continued service and follows the terms of the Inducement Equity Incentive Plan.
How many shares were covered by the inducement awards announced by BioCryst (BCRX)?
The inducement awards covered a combined 619,700 shares between options and RSUs. According to the company, that total comprises 251,150 stock options plus 368,550 restricted stock units granted on February 2, 2026.
Why were the equity awards issued under Nasdaq Listing Rule 5635(c)(4) for BioCryst (BCRX)?
The awards were issued as inducements material to each employee entering employment with BioCryst. According to the company, grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) which permits inducement awards for newly hired employees.
